Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Soleno Therapeutics stock

SLNO
US8342032005
A2JSTG

Price

49.68
Today +/-
+0.05
Today %
+0.10 %
P

Soleno Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Soleno Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Soleno Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Soleno Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Soleno Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Soleno Therapeutics Stock Price History

DateSoleno Therapeutics Price
10/2/202449.68 undefined
10/1/202449.63 undefined
9/30/202450.49 undefined
9/27/202449.13 undefined
9/26/202448.77 undefined
9/25/202448.78 undefined
9/24/202446.88 undefined
9/23/202448.14 undefined
9/20/202451.61 undefined
9/19/202452.73 undefined
9/18/202453.55 undefined
9/17/202452.92 undefined
9/16/202452.79 undefined
9/13/202452.84 undefined
9/12/202449.61 undefined
9/11/202448.58 undefined
9/10/202449.43 undefined
9/9/202448.75 undefined
9/6/202448.54 undefined
9/5/202449.92 undefined
9/4/202449.80 undefined

Soleno Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Soleno Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Soleno Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Soleno Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Soleno Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Soleno Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Soleno Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Soleno Therapeutics’s growth potential.

Soleno Therapeutics Revenue, EBIT and net profit per share

DateSoleno Therapeutics RevenueSoleno Therapeutics EBITSoleno Therapeutics Net Income
2026e144.47 M undefined5.94 M undefined-7.6 M undefined
2025e35.81 M undefined-86.44 M undefined-83.16 M undefined
2024e0 undefined-103.04 M undefined-95.8 M undefined
20230 undefined-41.38 M undefined-38.99 M undefined
20220 undefined-24.4 M undefined-24.07 M undefined
20210 undefined-31.53 M undefined-30.91 M undefined
20200 undefined-36.29 M undefined-24.64 M undefined
20190 undefined-23.49 M undefined-30.77 M undefined
20180 undefined-14.3 M undefined-13.34 M undefined
20170 undefined-12.17 M undefined-15.39 M undefined
20160 undefined-8.32 M undefined-15.72 M undefined
2015610,000 undefined-12.16 M undefined-15.91 M undefined
20140 undefined-5.16 M undefined-13.87 M undefined
20133 M undefined-850,000 undefined-3.71 M undefined
20120 undefined-3.6 M undefined-6.48 M undefined

Soleno Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e
030000000000035144
--------------311.43
---------------
000000000000000
-30-5-12-8-12-14-23-36-31-24-41-103-865
--------------245.713.47
-6-3-13-15-15-15-13-30-24-30-24-38-95-83-7
--50.00333.3315.38---13.33130.77-20.0025.00-20.0058.33150.00-12.63-91.57
0.090.090.090.130.210.61.42.284.175.328.416.49000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Soleno Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Soleno Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
2.161.277.965.492.7317.124.0820.7349.2221.314.6169.68
015001601300000000
15000000000000
001105506600000000
0.080.110.270.210.290.890.530.411.021.121.051.68
2.391.538.346.413.8117.9924.6121.1450.2422.4215.65171.36
1106060901002010440160450160419
000000000000
000000000000
0000.920.8220.4118.4716.5314.5812.6410.698.75
0007207200000000
2000801305900600400165
0.130.060.061.811.7721.0218.4817.0314.7413.1310.859.33
2.521.598.48.225.5839.0143.0938.1764.9835.5526.5180.69
                       
23.8123.810.010.010.020.020.030.050.080.080.010.03
19.219.2459.1489.46101.73140.49157.41172.71227.91231.07247.76433.89
-53.39-57.1-70.34-86.25-98.31-113.98-127.03-157.81-182.45-213.36-237.42-276.41
000000000000
000000000000
-10.38-14.05-11.193.223.4426.5330.4114.9545.5417.7910.35157.51
0.220.060.990.70.540.630.9323.493.251.783.15
0.190.130.21.631.170.970.942.594.934.435.056.8
0000.8700.1300.370.190.320.481.56
11.1313.990.1000000000
00000002010000
11.5414.181.293.21.711.731.874.988.6287.3111.5
0000000100000
000000000000
1.361.4618.31.780.4210.7510.8618.2510.829.758.8411.68
1.361.4618.31.780.4210.7510.8618.2610.829.758.8411.68
12.915.6419.594.982.1312.4812.7323.2419.4417.7516.1523.18
2.521.598.48.25.5739.0143.1438.1964.9835.5426.5180.69
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Soleno Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Soleno Therapeutics's financial health and stability.

Assets

Soleno Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Soleno Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Soleno Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Soleno Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-6-3-13-15-12-12-11-30-24-30-24-38
000001,0001,0001,0001,0001,0001,0001,000
000000000000
000000022-102
23950109-45415
000000000000
000000000000
-30-4-10-13-9-11-17-25-27-20-24
000000000000
000-100000000
000-100000000
000000000000
502000000000
001091023161453015180
501191023171453014180
00-2,0000001,000000-1,0000
000000000000
106-2-2145-228-27-6155
-3.5-0.89-4.51-10.36-13.54-9.95-11.69-17.4-25.23-27.79-20.79-24.94
000000000000

Soleno Therapeutics stock margins

The Soleno Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Soleno Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Soleno Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Soleno Therapeutics's sales revenue. A higher gross margin percentage indicates that the Soleno Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Soleno Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Soleno Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Soleno Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Soleno Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Soleno Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Soleno Therapeutics Margin History

Soleno Therapeutics Gross marginSoleno Therapeutics Profit marginSoleno Therapeutics EBIT marginSoleno Therapeutics Profit margin
2026e40.98 %4.11 %-5.26 %
2025e40.98 %-241.38 %-232.23 %
2024e40.98 %0 %0 %
202340.98 %0 %0 %
202240.98 %0 %0 %
202140.98 %0 %0 %
202040.98 %0 %0 %
201940.98 %0 %0 %
201840.98 %0 %0 %
201740.98 %0 %0 %
201640.98 %0 %0 %
201540.98 %-1,993.44 %-2,608.2 %
201440.98 %0 %0 %
201340.98 %-28.33 %-123.67 %
201240.98 %0 %0 %

Soleno Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Soleno Therapeutics earnings per share therefore indicates how much revenue Soleno Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Soleno Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Soleno Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Soleno Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Soleno Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Soleno Therapeutics Revenue, EBIT and net profit per share

DateSoleno Therapeutics Sales per ShareSoleno Therapeutics EBIT per shareSoleno Therapeutics Earnings per Share
2026e3.72 undefined0 undefined-0.2 undefined
2025e0.92 undefined0 undefined-2.14 undefined
2024e0 undefined0 undefined-2.46 undefined
20230 undefined-2.51 undefined-2.36 undefined
20220 undefined-2.9 undefined-2.87 undefined
20210 undefined-5.93 undefined-5.81 undefined
20200 undefined-8.7 undefined-5.91 undefined
20190 undefined-10.3 undefined-13.5 undefined
20180 undefined-10.21 undefined-9.53 undefined
20170 undefined-20.28 undefined-25.65 undefined
20160 undefined-39.62 undefined-74.86 undefined
20154.69 undefined-93.54 undefined-122.38 undefined
20140 undefined-57.33 undefined-154.11 undefined
201333.33 undefined-9.44 undefined-41.22 undefined
20120 undefined-40 undefined-72 undefined

Soleno Therapeutics business model

Soleno Therapeutics Inc is a biopharmaceutical company focused on rare diseases and unmet medical needs. The company was founded in 1999 and is headquartered in Redwood City, California. Soleno Therapeutics develops and markets innovative therapies for patients who have previously had limited or no treatment options. Business model: Soleno Therapeutics specializes in developing therapies for rare diseases. The company takes an innovative approach and utilizes cutting-edge technologies to develop drugs that have the potential to improve the lives of affected patients. The company works closely with leading research institutions and experts in the industry and invests significantly in research and development of new therapies. The company employs a two-pronged approach, developing innovative drugs for unmet medical needs while also acquiring already approved drugs and optimizing them for new applications. Soleno Therapeutics then markets these drugs to physicians, hospitals, and patients worldwide. Segments: Soleno Therapeutics specializes in developing therapies for rare diseases, focusing on three main segments: 1. Hypophosphatasia: Hypophosphatasia is a rare metabolic disorder that leads to the accumulation of phosphate in the bones and tissues. This results in weak bones, pain, and a variety of other symptoms. Soleno Therapeutics has developed a novel enzyme replacement therapy product that aims to support bone formation and alleviate the symptoms of the disease. 2. Prader-Willi Syndrome: Prader-Willi Syndrome is a rare genetic disorder characterized by obesity, mental retardation, and hormonal imbalances. Soleno Therapeutics has developed a product that suppresses hunger, helping patients develop a normal diet and achieve a healthy weight. 3. Other indications: Soleno Therapeutics is also working on developing therapies for other rare diseases and unmet medical needs, including conditions such as hemophilia, narcolepsy, and Parkinson's. Products: Soleno Therapeutics currently offers the following products: 1. Treakisym: Treakisym is a novel enzyme replacement therapy product aimed at supporting bone formation in patients with hypophosphatasia. The medication has already been approved in Japan. 2. Solinum: Solinum is a product that suppresses hunger in patients with Prader-Willi Syndrome. The medication is currently in Phase III of clinical trials and is expected to be approved in the coming years. 3. Other products: Soleno Therapeutics also has a range of other products in the pipeline, focusing on the development of therapies for rare diseases. Conclusion: Soleno Therapeutics is an innovative biopharmaceutical company specializing in the development of therapies for rare diseases and unmet medical needs. The company invests significantly in research and development of new medications and works closely with industry experts. Soleno Therapeutics has already launched an enzyme replacement therapy product for hypophosphatasia and is currently working on the approval of a hunger suppressant product for Prader-Willi Syndrome. The company also has a range of other medications in the pipeline, aiming to improve the lives of patients with rare diseases. Soleno Therapeutics is one of the most popular companies on Eulerpool.com.

Soleno Therapeutics SWOT Analysis

Strengths

Soleno Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare diseases. The company has a strong and dedicated team of researchers and scientists, well-versed in the field of rare diseases and drug development.

Soleno Therapeutics has a robust pipeline of potential drug candidates, targeting various rare diseases with limited treatment options. This diversification reduces the company's reliance on a single drug and provides opportunities for revenue growth.

The company has established strategic partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies. These collaborations allow Soleno Therapeutics to leverage external expertise, access additional resources, and share the risk and cost of drug development.

Weaknesses

Soleno Therapeutics Inc faces the challenge of limited financial resources. As a biopharmaceutical company, it requires substantial funding for research, clinical trials, and commercialization. The limited financial capacity may hinder the company's ability to progress its pipeline and compete with larger pharmaceutical companies.

The company's success heavily relies on the approval of its drug candidates by regulatory authorities, such as the FDA. Delays or failure to obtain regulatory approvals can significantly impact Soleno Therapeutics' timelines and financial performance.

Opportunities

Soleno Therapeutics Inc operates in a growing market of rare diseases, which presents significant unmet medical needs. The company is well-positioned to address these needs with its innovative drug candidates and potentially capture a substantial market share.

Advancements in genetic research and personalized medicine offer opportunities for Soleno Therapeutics to develop targeted therapies for specific rare diseases and patient populations. This approach could potentially enhance treatment efficacy and reduce side effects.

Threats

Soleno Therapeutics Inc operates in a highly competitive biopharmaceutical industry, where larger companies have more resources, established market presence, and greater marketing capabilities. This competitive landscape poses challenges in terms of market access, pricing, and attracting investors.

The company is also exposed to regulatory and legal risks, including stringent regulatory requirements, potential lawsuits, and intellectual property disputes. These factors can disrupt the company's operations, delay drug development, and affect its financial performance.

Soleno Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Soleno Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Soleno Therapeutics shares outstanding

The number of shares was Soleno Therapeutics in 2023 — This indicates how many shares 16.492 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Soleno Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Soleno Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Soleno Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Soleno Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Soleno Therapeutics stock splits

In Soleno Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Soleno Therapeutics.

Soleno Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.61 -0.57  (6.6 %)2024 Q2
3/31/2024-0.38 -0.59  (-57.04 %)2024 Q1
12/31/2023-0.28 -0.33  (-18.36 %)2023 Q4
9/30/2023-0.59 -0.95  (-61.51 %)2023 Q3
6/30/2023-0.84 -0.81  (3.94 %)2023 Q2
3/31/2023-0.74 -0.88  (-19 %)2023 Q1
12/31/2022-0.82 -0.58  (28.92 %)2022 Q4
9/30/2022-0.93 -0.76  (18.12 %)2022 Q3
6/30/2022-0.92 -0.9  (1.96 %)2022 Q2
3/31/2022-1.07 -1.08  (-0.84 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Soleno Therapeutics stock

Eulerpool World ESG Rating (EESG©)

35/ 100

🌱 Environment

37

👫 Social

41

🏛️ Governance

27

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Soleno Therapeutics shareholders

%
Name
Stocks
Change
Date
7.90981 % Perceptive Advisors LLC3,074,542012/31/2023
7.35221 % Abingworth Management Limited2,857,804012/31/2023
7.34847 % Nantahala Capital Management, LLC2,856,3512,463,94712/31/2023
6.49317 % Janus Henderson Investors2,523,897319,84412/31/2023
4.69980 % Adage Capital Management, L.P.1,826,814499,81412/31/2023
3.34448 % Vestal Point Capital, LP1,300,0001,300,00012/31/2023
21.65704 % Vivo Capital, LLC8,418,093012/31/2023
2.48827 % The Vanguard Group, Inc.967,191911,94012/31/2023
2.38455 % Balyasny Asset Management LP926,876468,05312/31/2023
2.01955 % Avoro Capital Advisors LLC785,000785,00012/31/2023
1
2
3
4
5
...
10

Soleno Therapeutics Executives and Management Board

Dr. Anish Bhatnagar55
Soleno Therapeutics President, Chief Executive Officer, Chief Operating Officer, Director (since 2006)
Compensation 1.13 M
Ms. Kristen Yen54
Soleno Therapeutics Vice President - Clinical Operations
Compensation 821,666
Mr. James Mackaness59
Soleno Therapeutics Chief Financial Officer
Compensation 626,195
Ms. Patricia Hirano57
Soleno Therapeutics Vice President - Regulatory Affairs
Compensation 476,934
Dr. Ernest Mario84
Soleno Therapeutics Independent Chairman of the Board (since 2007)
Compensation 84,956
1
2
3

Most common questions regarding Soleno Therapeutics

What values and corporate philosophy does Soleno Therapeutics represent?

Soleno Therapeutics Inc represents a commitment to improving the lives of patients by developing innovative therapies. The company focuses on addressing unmet medical needs in rare diseases, with a particular emphasis on neurodevelopmental and metabolic disorders. Soleno Therapeutics Inc strives for excellence in research and development, aiming to bring groundbreaking treatments to market. With a patient-centered approach, the company aims to provide hope and improve outcomes for individuals and families affected by these conditions. Soleno Therapeutics Inc envisions a future where better treatments are accessible to all, advocating for improved healthcare and quality of life.

In which countries and regions is Soleno Therapeutics primarily present?

Soleno Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Soleno Therapeutics achieved?

Soleno Therapeutics Inc has achieved several significant milestones in its journey. The company successfully developed a novel therapeutic candidate, Diazoxide Choline Controlled-Release (DCCR), to treat Prader-Willi Syndrome (PWS). In clinical studies, DCCR demonstrated promising results by addressing hyperphagia, a critical symptom of PWS. Soleno Therapeutics Inc also received Orphan Drug Designation for DCCR from the FDA, recognizing the potential to treat a rare and serious condition. The company continues to advance DCCR's development and explore its potential in other indications. Soleno Therapeutics Inc's commitment to innovation and dedication towards addressing unmet medical needs underscores its remarkable achievements in the field.

What is the history and background of the company Soleno Therapeutics?

Soleno Therapeutics Inc is a biopharmaceutical company based in California, United States. It was founded in 1999 under the name Capnia, Inc and changed its name to Soleno Therapeutics in 2017. The company specializes in developing innovative therapeutic solutions for rare diseases. Soleno Therapeutics focuses on areas such as neurology, endocrinology, and rare genetic diseases. They aim to transform patients' lives by delivering effective treatments. With a dedicated team of researchers and scientists, Soleno Therapeutics is committed to providing novel therapies to address unmet medical needs. Soleno Therapeutics Inc has made significant strides in the field of rare diseases and continues to contribute to advancements in healthcare.

Who are the main competitors of Soleno Therapeutics in the market?

Soleno Therapeutics Inc faces competition from several companies in the market. Some of its main competitors include companies such as Neurocrine Biosciences, Novo Nordisk, and Ascendis Pharma. These companies are also involved in the development and commercialization of innovative therapies and treatments for various medical conditions. However, Soleno Therapeutics Inc differentiates itself through its unique product offerings and focus on specific areas of medical need. It strives to provide effective solutions and improve patient outcomes, making it a formidable player in the competitive landscape.

In which industries is Soleno Therapeutics primarily active?

Soleno Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Soleno Therapeutics?

The business model of Soleno Therapeutics Inc revolves around developing and commercializing innovative therapeutic products for rare diseases. As a biopharmaceutical company, Soleno focuses on identifying, acquiring, and advancing promising technologies to address unmet medical needs. By leveraging its expertise in drug development and medical research, Soleno aims to bring novel and effective treatments to patients suffering from rare diseases. Through strategic collaborations, clinical trials, and regulatory approvals, Soleno Therapeutics Inc strives to improve the quality of life for individuals affected by these conditions.

What is the P/E ratio of Soleno Therapeutics 2024?

The Soleno Therapeutics P/E ratio is -8.55.

What is the P/S ratio of Soleno Therapeutics 2024?

The Soleno Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Soleno Therapeutics?

The AlleAktien quality score for Soleno Therapeutics is 2/10.

What is the revenue of Soleno Therapeutics 2024?

The revenue cannot currently be calculated for Soleno Therapeutics.

How high is the profit of Soleno Therapeutics 2024?

The expected Soleno Therapeutics profit is -95.8 M USD.

What is the business model of Soleno Therapeutics

Soleno Therapeutics Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare diseases. The company was founded in 1999 and is headquartered in Redwood City, California. Soleno Therapeutics focuses on developing therapies for rare diseases that have often been neglected by the pharmaceutical industry. The company currently offers two products: DiaPep277, an immunotherapy for the treatment of type 1 diabetes, and Caz-Avi, an antimicrobial therapy for the treatment of gram-negative bacterial infections. To successfully market these products, Soleno Therapeutics has two main business areas: research and development, and sales and marketing. The research and development department is responsible for identifying, developing, and testing new therapy approaches. The company has an experienced team of scientists and developers who pursue innovative approaches in therapy development. Soleno Therapeutics's sales and marketing department is responsible for effectively marketing the products and building a network of doctors and hospitals to increase sales. The company has a dedicated team of sales and marketing experts who work closely with medical professionals to ensure that the products provide the best possible patient care. Soleno Therapeutics has also established strong partnerships with other pharmaceutical companies and research institutions to accelerate the development of therapies for rare diseases. The company collaborates with these partners to carry out joint research and development projects and exchange ideas to speed up therapy development. Soleno Therapeutics is a successful biopharmaceutical company specializing in the development of therapies for rare diseases. The company has a strong pipeline of innovative products and works closely with its partners to accelerate therapy development. Soleno Therapeutics remains committed to expanding comprehensive treatment for patients with rare diseases.

What is the Soleno Therapeutics dividend?

Soleno Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Soleno Therapeutics pay dividends?

The dividend cannot currently be calculated for Soleno Therapeutics or the company does not pay out a dividend.

What is the Soleno Therapeutics ISIN?

The ISIN of Soleno Therapeutics is US8342032005.

What is the Soleno Therapeutics WKN?

The WKN of Soleno Therapeutics is A2JSTG.

What is the Soleno Therapeutics ticker?

The ticker of Soleno Therapeutics is SLNO.

How much dividend does Soleno Therapeutics pay?

Over the past 12 months, Soleno Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Soleno Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Soleno Therapeutics?

The current dividend yield of Soleno Therapeutics is .

When does Soleno Therapeutics pay dividends?

Soleno Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Soleno Therapeutics?

Soleno Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Soleno Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Soleno Therapeutics located?

Soleno Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Soleno Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Soleno Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Soleno Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Soleno Therapeutics in the year 2023?

In the year 2023, Soleno Therapeutics distributed 0 USD as dividends.

In which currency does Soleno Therapeutics pay out the dividend?

The dividends of Soleno Therapeutics are distributed in USD.

All fundamentals about Soleno Therapeutics

Our stock analysis for Soleno Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Soleno Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.